Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1003

1.

Rivaroxaban: an oral factor Xa inhibitor.

Thomas TF, Ganetsky V, Spinler SA.

Clin Ther. 2013 Jan;35(1):4-27. doi: 10.1016/j.clinthera.2012.12.005. Review.

PMID:
23328267
2.

Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).

Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW.

J Am Coll Cardiol. 2013 Feb 12;61(6):651-8. doi: 10.1016/j.jacc.2012.09.057.

4.

The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.

Cohen AT, Dobromirski M.

Thromb Haemost. 2012 Jun;107(6):1035-43. doi: 10.1160/TH11-12-0859. Epub 2012 Feb 28. Review.

PMID:
22371186
5.

The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.

Reddy P, Giugliano RP.

J Cardiovasc Pharmacol Ther. 2014 Nov;19(6):526-32. doi: 10.1177/1074248414525505. Epub 2014 Mar 21. Review.

PMID:
24659084
6.

Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.

Becattini C, Vedovati MC, Agnelli G.

Thromb Res. 2012 Mar;129(3):392-400. doi: 10.1016/j.thromres.2011.12.014. Epub 2012 Jan 20. Review.

PMID:
22264937
7.

Rivaroxaban, an oral direct factor Xa inhibitor.

Piccini JP, Patel MR, Mahaffey KW, Fox KA, Califf RM.

Expert Opin Investig Drugs. 2008 Jun;17(6):925-37. doi: 10.1517/13543784.17.6.925 . Review.

PMID:
18491993
8.

Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.

Cheng JW, Barillari G.

J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3. Review.

PMID:
24383983
9.

Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).

Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA; ROCKET AF Steering Committee and Investigators.

Circulation. 2014 Jul 8;130(2):138-46. doi: 10.1161/CIRCULATIONAHA.113.005008. Epub 2014 Jun 3.

10.

Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.

Loke YK, Kwok CS.

J Clin Pharm Ther. 2011 Feb;36(1):111-24. doi: 10.1111/j.1365-2710.2010.01162.x. Review.

PMID:
21198726
11.

Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism.

Yong CM, Boyle AJ.

Curr Vasc Pharmacol. 2010 Jan;8(1):5-11. Review.

PMID:
19485937
12.

Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry.

Beyer-Westendorf J, Lützner J, Donath L, Radke OC, Kuhlisch E, Hartmann A, Weiss N, Werth S.

J Thromb Haemost. 2012 Oct;10(10):2045-52. doi: 10.1111/j.1538-7836.2012.04877.x.

13.

Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.

Levitan B, Yuan Z, Turpie AG, Friedman RJ, Homering M, Berlin JA, Berkowitz SD, Weinstein RB, DiBattiste PM.

Vasc Health Risk Manag. 2014 Mar 26;10:157-67. doi: 10.2147/VHRM.S54714. eCollection 2014.

14.

[Rivaroxaban in the prevention and treatment of thromboembolic disorders].

Helbing T, Bode C, Moser M.

Hamostaseologie. 2012;32(3):195-202. doi: 10.5482/HAMO-12-05-0005. Epub 2012 Jul 10. German.

PMID:
22777255
15.

Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis.

Kwong LM.

Orthopedics. 2012 Jun;35(6):e932-8;discussion e939. doi: 10.3928/01477447-20120525-38.

PMID:
22691670
16.

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

Lip GY, Larsen TB, Skjøth F, Rasmussen LH.

J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9.

17.
18.

Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.

Messori A, Fadda V, Maratea D, Trippoli S, Marinai C.

Int J Clin Pharmacol Ther. 2015 Mar;53(3):211-9. doi: 10.5414/CP202183. Review.

PMID:
25295718
19.

Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk.

Haas S, Bode C, Norrving B, Turpie AG.

Vasc Health Risk Manag. 2014 Mar 10;10:101-14. doi: 10.2147/VHRM.S55246. eCollection 2014. Review.

20.

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.

Supplemental Content

Support Center